title: Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
authors.affiliation: Department of radiation oncology, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Géraud
authors.affiliation: Department of radiation oncology, institut Curie, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: H P
authors.initials: HP
authors.lastname: Xu
authors.affiliation: Department of medical oncology, 26, rue d'Ulm, 75005 Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Beuzeboc
authors.affiliation: Department of radiation oncology, institut Curie, 26, rue d'Ulm, 75005 Paris, France. Electronic address: youlia.kirova@curie.fr.
authors.forename: Y M
authors.initials: YM
authors.lastname: Kirova
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D059248:Chemoradiotherapy; D005260:Female; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000069473:Radiation Dose Hypofractionation; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab
chemical_list: D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Concurrent treatment; Metastatic breast cancer; Radiotherapy; TDM1; Toxicity